XBiotech Inc. XBIT
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
XBiotech Inc. (XBIT) is a healthcare company listed in the US with a market value of about $60M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -18%.
About XBiotech
XBiotech is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. It was profitable in 1 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $4M | $18M | $44M | — | $0 | — | — |
| Net income | -$46M | -$39M | -$25M | -$33M | -$17M | -$11M | $669M | -$21M | -$33M | -$53M |
| Free cash flow | -$40M | -$32M | -$19M | -$15M | $66M | -$69M | -$18M | -$17M | -$35M | -$51M |
| EPS (diluted) | $-1.49 | $-1.26 | $-0.81 | $-1.08 | $-0.58 | $-0.36 | $14.44 | $-0.59 | $-0.95 | $-1.63 |
| Net margin | — | — | — | -820.4% | -94.7% | -25.5% | — | — | — | — |
| ROIC | -31.3% | -23.3% | -13.5% | -14.1% | -6.4% | -4.6% | -3.9% | -50.7% | -56.6% | -89.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does XBiotech pay a dividend?
Not currently.
Is XBiotech a good stock to buy?
We do not give buy or sell advice. XBiotech scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.